Insider trade

CFO purchased ~$201K of ABT shares in the open market

Traded Apr 23, 2026 · Filed Apr 27, 2026

~$201K
Reported value · 2,200 sh @ $91.50: 2,200
Holds after · shares reported

Why it stands out

The money chief of Abbott Laboratories spent $201K of their very own money to buy Abbott Laboratories shares. 2 other people at Abbott Laboratories bought some too, in the same month.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 23, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 27, 2026

CFOIndirect holding$100K–$500K3 insiders bought in 30d

Context

Classification

open market purchase

Code P — open-market or private purchase

Absolute commitment

~$201,300

Shares × reported transaction price

Size band

$100K–$500K

Rarity

Not enough history to judge

Confirmed open-market purchases by the same insider in the available history

Cluster activity

3 distinct insiders in 30 days

Distinct insiders at the same issuer with confirmed open-market purchases

Size vs officer pay

This purchase equals about 2.7% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($7.46M)

An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-13. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement

Timing vs results

7 days after results of Apr 16, 2026, 84 days before results of Jul 16, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred